Monopar Therapeutics Inc. (MNPR)
Develops cancer drugs using radioactive antibodies to target and destroy tumors.
$109.09-0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+168.1%
The outlook
Mnpr trades near the top of its 52-week range, well above both its 50- and 200-day averages. Analyst consensus leans strongly bullish, with an average price target sitting about 7% above the current price. The stock is trading at elevated levels relative to its recent historical range.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range91% of the way from its 52-week low to high
Price targetAvg target +7% vs current price
Analyst price target
~12-month · 13 analysts$116.85average target+7.1% vs now
Now $109.09
Low $100.00High $130.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$730.8M
52-wk high
$116.64
52-wk low
$29.18
50-day avg
$80.53
200-day avg
$70.79
Trailing P/E
—